ES2436246B2 - Cosmetic composition for the care and treatment of alopecia - Google Patents
Cosmetic composition for the care and treatment of alopecia Download PDFInfo
- Publication number
- ES2436246B2 ES2436246B2 ES201331311A ES201331311A ES2436246B2 ES 2436246 B2 ES2436246 B2 ES 2436246B2 ES 201331311 A ES201331311 A ES 201331311A ES 201331311 A ES201331311 A ES 201331311A ES 2436246 B2 ES2436246 B2 ES 2436246B2
- Authority
- ES
- Spain
- Prior art keywords
- cosmetic composition
- alopecia
- acid
- composition according
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 40
- 239000002537 cosmetic Substances 0.000 title claims abstract description 30
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 14
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001948 caffeine Drugs 0.000 claims abstract description 13
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004475 Arginine Substances 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 10
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical compound OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000003751 zinc Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 3
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 3
- 235000010582 Pisum sativum Nutrition 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 241000219843 Pisum Species 0.000 claims description 13
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 229940068977 polysorbate 20 Drugs 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 240000004713 Pisum sativum Species 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 5
- 229960002079 calcium pantothenate Drugs 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001083 diazolidinylurea Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 claims 1
- 210000004209 hair Anatomy 0.000 description 25
- 210000004761 scalp Anatomy 0.000 description 18
- 210000003780 hair follicle Anatomy 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 201000002996 androgenic alopecia Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 206010068168 androgenetic alopecia Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 208000003024 Diffuse alopecia Diseases 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003646 hair health Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000002948 pantothenic acids Chemical class 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- -1 Diazolidinyl Chemical group 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GKFNXYMAMKJSKD-NHCYSSNCSA-N Lys-Asp-Val Chemical group [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GKFNXYMAMKJSKD-NHCYSSNCSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000282487 Vulpes Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 239000006272 natural pesticide Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- CHCZPSBPZFXDQJ-UHFFFAOYSA-L zinc;2-oxopyrrolidine-1-carboxylate Chemical compound [Zn+2].[O-]C(=O)N1CCCC1=O.[O-]C(=O)N1CCCC1=O CHCZPSBPZFXDQJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición cosmética que comprende una cantidad cosméticamente efectiva de extracto orgánico de guisante, sal de zinc del ácido pirrolidoncarboxílico, arginina, cafeína y sales de ácido pantoténico para la preparación de una composición cosmética para el cuidado y tratamiento de la alopecia y al método de administración de la misma.The present invention relates to a cosmetic composition comprising a cosmetically effective amount of organic pea extract, zinc salt of pyrrolidoncarboxylic acid, arginine, caffeine and salts of pantothenic acid for the preparation of a cosmetic composition for the care and treatment of the alopecia and the method of administration thereof.
Description
OBJETO DE LA INVENCIÓN OBJECT OF THE INVENTION
La presente invención se refiere al uso de una composición cosmética que comprende una cantidad cosmética mente efectiva de extracto orgánico de guisante, de sal de zinc del ácido pirrolidoncarboxilico (zinc PCA), de arginina, de cafeina y de sales de ácido The present invention relates to the use of a cosmetic composition comprising a cosmetically effective amount of organic pea extract, zinc salt of pyrrolidoncarboxylic acid (PCA zinc), arginine, caffeine and acid salts
piel o cuero cabelludo de dicha composición que comprende las etapas de tomar una skin or scalp of said composition comprising the steps of taking a
muestra de la composición cosmética con un dispositivo de aplicación y aplicar de fonna localizada sobre la zona afectada con alopecia en fonna de espuma mediante un ligero masaje, de fonna preferida antes de acostarse. Sample of the cosmetic composition with an application device and apply of fonna located on the affected area with alopecia in foam fonna by means of a light massage, of preferred fonna before bedtime.
ANTECEDENTES DE LA INVENCIÓN BACKGROUND OF THE INVENTION
La alopecia es una afección que conlleva la pérdida anonnal o rarefacción del vello, por lo que el término se considera un sinónimo de calvicie o caída del cabello. Puede afectar al cuero cabelludo o a otras zonas de la piel en la que existe pelo, como las pestañas, Alopecia is a condition that leads to anonnal loss or rarefaction of hair, so the term is considered a synonym for baldness or hair loss. It can affect the scalp or other areas of the skin where there is hair, such as eyelashes,
axilas, región genital y barba. El ténnino alopecia deriva de la palabra griega alopex. armpits, genital region and beard. The Tennino Alopecia derives from the Greek word Alopex.
La alopecia puede clasificarse en multitud de grupos, sebTÚn su origen y manifestaciones, pero la fOlma más frecuente es la alopecia androgénica, también llamada alopecia androgenética o calvicie común, que es responsable del 95% de los casos y afecta principalmente a los varones, menos frecuentemente a las mujeres, y debe su nombre a que está provocada por la acción de las hormonas masculinas o andrógenos sobre el folículo piloso, provocando su miniaturización progresiva. Alopecia can be classified into a multitude of groups, depending on their origin and manifestations, but the most frequent form is androgenic alopecia, also called androgenetic alopecia or common baldness, which is responsible for 95% of cases and mainly affects men, less frequently to women, and owes its name to that it is caused by the action of male hormones or androgens on the hair follicle, causing its progressive miniaturization.
En la alopecia androgenética, las responsables de la caída del cabello son la enzima 5alfa-reductasa y la honnona testosterona. La enzima convierte la testosterona en dihidrotestosterona (DHT) quien finalmente se encarga de reducir los folículos haciendo que las membranas del cuero cabelludo se tomen rígidas_ In androgenetic alopecia, those responsible for hair loss are the enzyme 5alpha reductase and honnone testosterone. The enzyme converts testosterone into dihydrotestosterone (DHT), which ultimately reduces follicles by making the scalp membranes stiff.
5 De esta forma, la estructura folicular recibe menos irrigación sanguínea y los cabellos nuevos son más débiles y finos de lo nonnal. Al final del proceso, los folículos se atrofian y el cabello que se cae no es reemplazado por cabello nuevo. 5 In this way, the follicular structure receives less blood supply and the new hair is weaker and thinner than the nonnal. At the end of the process, the follicles atrophy and the hair that falls out is not replaced by new hair.
lOSe han estudiado los niveles de DHT en personas con alopecia androgenética y suelen ser normales. Por lo tanto, la ciencia ha detenninado que no es un nivel elevado de DHT lo que produce la alopecia sino una sensibilidad particular de los folículos frente a la OHI. The levels of DHT have been studied in people with androgenetic alopecia and are usually normal. Therefore, science has determined that it is not a high level of DHT that produces alopecia but a particular sensitivity of the follicles to the IHO.
Los tratamientos que inhiben la enzima 5-alfa-reductasa tienen buenos resultados Treatments that inhibit the enzyme 5-alpha-reductase have good results
15 justamente porque evitan la producción de OHT. Los folículos pilosos reciben testosterona y sangre de los vasos capilares. La enzima 5-alfa-reductasa (5ar) convierte la testos terona en OHT. 15 precisely because they avoid the production of OHT. The hair follicles receive testosterone and blood from the capillaries. The enzyme 5-alpha-reductase (5ar) converts the terone testes to OHT.
En los hombres predispuestos genéticamente a la pérdida de cabello, cuando los niveles 20 de OHT suben pasa lo siguiente: In men genetically predisposed to hair loss, when OHT levels 20 rise, the following happens:
- --
- Se acorta el tiempo de la fase de crecimiento (Amigena). -Los folículos se achican produciendo un cabello más fino. La cantidad de cabellos visibles se reduce. The time of the growth phase is shortened (Amigena). -The follicles shrink producing finer hair. The amount of visible hair is reduced.
25 Otras fonnas comunes de alopecia son la alopecia areala, en la que la pérdida del pelo no es definitiva y se circunscribe comúnmente a un área detenninada, la alopecia universal que es la forma extensa de la alopecia areala y la alopecia cicatricial que está provocada por una destrucción del folículo piloso y es por lo tanto in-eversible_ Existen 25 Other common sources of alopecia are alopecia areala, in which hair loss is not definitive and is commonly confined to a detained area, universal alopecia, which is the extensive form of alopecia areala and the scarring alopecia that is caused by a destruction of the hair follicle and is therefore inescapable_ There are
30 muchas variedades de alopecia de presentación menos frecuente que pueden estar 30 many varieties of less frequent presentation alopecia that may be
originadas por causas genéticas, medicamentos, infecciones cutáneas, traumatismos, deficiencias nutritivas y ciertas enfennedades de la piel o generales. originated by genetic causes, medications, skin infections, trauma, nutritional deficiencies and certain skin or general diseases.
El pelo humano presenta tres etapas en su desarrollo normal, la primera y más larga es la Human hair has three stages in its normal development, the first and longest is the
fase anágeno que dura entre 2 y 6 años, durante la cual el pelo crece un centímetro al mes por ténnino medio, le sigue la fase catágeno o de reposo que dura 20 días y por último el cabello entra en fase de telógeno o caída, periodo que dura alrededor de 3 meses. Por télmino medio en un día se pierden alrededor de 40-60 cabellos, que en condiciones nonnales van siendo sustituidos otros nuevos que fabrica el folículo piloso. anagen phase that lasts between 2 and 6 years, during which the hair grows one centimeter per month by medium tenin, followed by the catagen or resting phase that lasts 20 days and finally the hair enters telogen or fall phase, period It lasts about 3 months. On average, in one day about 40-60 hairs are lost, which under new conditions are replaced by new ones manufactured by the hair follicle.
Cada cabello crece de un folículo piloso y cada folículo piloso sigue su propio ciclo que es independiente de los que están a su alrededor, por ello en un momento determinado, Each hair grows from a hair follicle and each hair follicle follows its own cycle that is independent of those around it, so at a certain time,
de una persona sin alopecia ex isten entre 100.000 y 150.000 cabellos, de ellos el 85% of a person without alopecia there are between 100,000 and 150,000 hairs, 85% of them
están en fase anagén o período de crecimiento, el 1-2% en catagén o fase de reposo y el they are in anagén phase or growth period, 1-2% in catagen or resting phase and the
13-14% en fase telogén o de caída. 13-14% in telogén or fall phase.
Entre los documentos de patentes que hay publicados referidos a composiciones cosméticas destinadas al tratamiento de la alopecia, encontramos el documento W020 13028049 que se refiere a una composición de aplicación percutánea de forma líquida que comprende Minoxidil, Tretinoina, Propionato de Clobetazol y Finasterida como principios activos, además de un cosurfactante tal como el éter monoetílico de dietilenglicol (Transcutol P) como potenciador para su aplicación en el tratamiento de la alopecia, un vehículo transportador, y coadyuvantes para su uso en el tratamiento principalmente de la alopecia androgenética. Among the published patent documents referring to cosmetic compositions intended for the treatment of alopecia, we find document W020 13028049 which refers to a percutaneous liquid composition comprising Minoxidil, Tretinoin, Clobetazole Propionate and Finasteride as active ingredients , in addition to a cosurfactant such as diethylene glycol monoethyl ether (Transcutol P) as an enhancer for application in the treatment of alopecia, a carrier, and adjuvants for use in the treatment of androgenetic alopecia.
La patente EPI663285 validada en España con el número ES2401686 se refiere a la Patent EPI663285 validated in Spain with the number ES2401686 refers to the
utilización de conjugados peptídicos que contienen la secuencia Gly-His-Lys para la preparación de composiciones dennatológ icas O cosmetológicas para estimular el use of peptide conjugates containing the Gly-His-Lys sequence for the preparation of dennatological or cosmetological compositions to stimulate the
crecimiento del cabello o frenar su caída. Los péptidos o sus conjugados peptídicos Hair growth or slow down your fall. Peptides or their peptide conjugates
pueden ser administrados para su utilización cosmética por vía tópica. They can be administered for cosmetic use topically.
Existe también la patente EP 1646651 validada en España con el numero ES2399048 que tiene por objeto nuevos conjugados peptídicos que contienen las secuencias Lys-Asp-Val, útiles en dennatología o cosmetología, en particular para estimular el crecimiento del cabello o frenar su caída. La composición cosmética o dennatológica puede, por ejemplo, presentarse en fonna de una loción, de un champú de tratamiento, de un spray, de un gel o de una crema de tratamiento. There is also the patent EP 1646651 validated in Spain with the number ES2399048 which aims at new peptide conjugates containing the Lys-Asp-Val sequences, useful in dennatology or cosmetology, in particular to stimulate hair growth or stop hair loss. The cosmetic or dennatological composition may, for example, be presented in the form of a lotion, a treatment shampoo, a spray, a gel or a treatment cream.
La patente EP1427383 tiene por objeto un método cosmético para impedir o reducir la gravedad de la alopecia inducida por quimioterapia en un paciente humano o un animal mamífero que deba ser sometido a tratamiento con quimioterapia de un tumor no residente en el cuero cabelludo del paciente O la piel del animal, el método comprendiendo administrar al cuero cabelludo del paciente o la piel del animal una composición que comprende un inductor químico de la respuesta de las proteínas de estrés, donde la composición es administrada en una cantidad y en un momento suficientemente antes de la administración de un fármaco quimioterapéutico para producir una mayor resistencia de los folículos pilosos en el cuero cabelludo o piel al fánnaco en el momento de la administración del fánnaco. The patent EP1427383 is aimed at a cosmetic method to prevent or reduce the severity of chemotherapy-induced alopecia in a human patient or a mammalian animal that must undergo chemotherapy treatment of a tumor not resident in the patient's scalp OR animal skin, the method comprising administering to the patient's scalp or animal's skin a composition comprising a chemical inducer of the stress protein response, where the composition is administered in an amount and at a time sufficiently before the administration of a chemotherapeutic drug to produce greater resistance of the hair follicles in the scalp or skin to the drug at the time of administration of the drug.
En relación con la alopecia androgenética y difusa de tipo femenino se encuentra el documento de patente europea EPI235571 que se refiere a la utilización de una composición, que consta de melatonina, apropiadas sustancias de vehículo, diluyentes y auxiliares, así como de vitaminas, para la preparación de un agente destinado al tratamiento de las alopecias androgenética y difusa del tipo femenino. La invención también se refiere a la utilización de melatonina con el fin de aumentar el diámetro del pelo o/y de elevar la capacidad de alargamiento o/y de elevar el número de folículos pilosos anágenos en el caso de una alopecia difusa, en particular en el caso de pelos occipitales y de pacientes femeninas. In relation to androgenetic and diffuse female alopecia is European patent document EPI235571 which refers to the use of a composition, consisting of melatonin, appropriate vehicle substances, diluents and auxiliaries, as well as vitamins, for the preparation of an agent for the treatment of androgenetic and diffuse alopecia of the female type. The invention also relates to the use of melatonin in order to increase the diameter of the hair or / and to increase the elongation capacity or / and to increase the number of anagen hair follicles in the case of diffuse alopecia, in particular in the case of occipital hairs and female patients.
Otro documento relevante en el estado del arte es el documento de patente ES2l43437 que se refiere a un producto para tratamiento de la alopecia, procedimiento para la obtención del mismo y método de aplicación. El producto consiste en un extracto acuoso vegetal, concretamente de Agrimonia eupatoria L., obtenido mediante cocción de las hojas de dicha planta, en agua, durante un tiempo comprendido entre 20 y 30 minutos a partir del momento en que comienza la ebullición, tras lo que se eliminan las hojas y los residuos sólidos, mediante filtrado, procediéndose finalmente a su envasado tras su enfriamiento hasta la temperatura ambiente. El producto resultante se aplica al cuero cabelludo y se deja actuar durante un tiempo comprendido entre 18 y 20 horas, tras lo que se procede a su aclarado. Another relevant document in the state of the art is patent document ES2l43437 which refers to a product for the treatment of alopecia, procedure for obtaining it and method of application. The product consists of an aqueous vegetable extract, specifically of Agrimonia eupatoria L., obtained by cooking the leaves of said plant, in water, for a time between 20 and 30 minutes from the moment the boiling begins, after that the leaves and solid waste are removed, by filtration, finally being packed after cooling to room temperature. The resulting product is applied to the scalp and allowed to act for a time between 18 and 20 hours, after which it is rinsed.
Si leemos en detalle todos estos documentos del estado de la técnica ninguno de ellos hace alusión a la combinación propuesta por los inventores de la presente invención, en particular ninguno de los documentos citados anterionnente se refieren a una composición cosmética que comprende una cantidad cosmética mente efectiva de los siguientes componentes: extracto orgánico de guisante, de sal de zinc del ácido pirrolidoncarboxílico (zinc peA), de arginina, de cafeína y de sales de ácido pantoténico. If we read in detail all these documents of the prior art none of them alludes to the combination proposed by the inventors of the present invention, in particular none of the documents cited above refer to a cosmetic composition comprising a cosmetically effective amount of the following components: organic pea extract, zinc salt of pyrrolidoncarboxylic acid (zinc peA), arginine, caffeine and pantothenic acid salts.
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN DETAILED DESCRIPTION OF THE INVENTION
En la actualidad son frecuentes los problemas de alopecia, con las consiguientes molestias que ello conlleva para los pacientes afectados, en su estado fisico, además de las limitaciones a que da lugar, coartando en muchos casos la actividad, con impedimento incluso para el desarrollo de detenninadas funciones de trabajo, deporte, etc. Nowadays, alopecia problems are frequent, with the consequent discomforts that this entails for the affected patients, in their physical state, in addition to the limitations that it gives rise, in many cases restricting the activity, with impediment even for the development of arrested functions of work, sport, etc.
En este sentido para paliar en lo posible esas molestias y consecuencias perjudiciales de la alopecia sobre todo por el efecto antiestético, de acuerdo con el objeto de la presente invención se propone una composición tópica, de acción cosmética que resulta muy In this sense, to alleviate as much as possible these discomforts and harmful consequences of alopecia, especially due to the unsightly effect, in accordance with the object of the present invention, a topical composition with a cosmetic action is proposed, which is very
ventajosa para aminorar los mencionados efectos. advantageous to reduce the aforementioned effects.
fonnulada a base de extractos y compuestos de origen natural y sostenible, lo cual hace Fonnulate based on extracts and compounds of natural and sustainable origin, which makes
además posible su uso continuado sin que ocasione efectos secundarios, tales como atrofiamiento de la piel e irritaciones en el cuero cabelludo. In addition, its continued use is possible without causing side effects, such as skin atrophy and irritation of the scalp.
Un aspecto importante de la presente invención es que se refiere a una composición cosmética que comprende una cantidad cosméticamente efectiva de extracto orgánico de An important aspect of the present invention is that it refers to a cosmetic composition comprising a cosmetically effective amount of organic extract of
guisante, de sal de zinc del ácido pirrolidoncarboxílico (zinc PCA), de arginina, de pea, pyrrolidoncarboxylic acid zinc salt (PCA zinc), arginine,
cosmética para el cuidado y tratamiento de la alopecia. Cosmetic for the care and treatment of alopecia.
De acuerdo con otro aspecto importante de la presente invención se refiere a una According to another important aspect of the present invention it refers to a
composición cosmética para el cuidado y tratamiento de la alopecia que comprende los siguientes componentes en las siguientes proporciones, de manera que la suma de los mismos no supere el 100% de la composición: cosmetic composition for the care and treatment of alopecia comprising the following components in the following proportions, so that the sum thereof does not exceed 100% of the composition:
- Fracción activa de extracto orgánico de Active fraction of organic extract of
- brotes de g ui sante gui sante shoots
- (Pisum sativum): entre O, I 0% Y 5,00 % (Pisum sativum): between O, I 0% and 5.00%
- Pantotenato Cá lcico: Calcium Pantothenate:
- entre 0, 10% y 1,50 % between 0, 10% and 1.50%
- Arginina: Arginine:
- entre 0, 10% y 1,50% between 0, 10% and 1.50%
- Cafeína: Caffeine:
- 0,50% 0.50%
- Acido Pirrolidoncarboxílico, sal de Zinc: Pyrrolidoncarboxylic acid, Zinc salt:
- entre 0,50% y 4,00% between 0.50% and 4.00%
- Conservante: Preservative:
- entre O, I 0% Y0,50% between O, I 0% Y0.50%
- Acido Cítrico a pH 5,5: Citric Acid at pH 5.5:
- entre 0,010% y 0,50% between 0.010% and 0.50%
- Agua: Water:
- q.s. q.s.
Urea, Benzoato Sódico, Metilparaben y Propilparaben. Urea, Sodium Benzoate, Methylparaben and Propilparaben.
De forma preferida, la presente composición contiene un sistema tensioactivo fonnado por una combinación de Laurileter Sulfato Sódico y Polisorbato-20, que aumenta y mejora el contacto de los principios activos sobre el cuero cabelludo, incrementando sus niveles de penetración intradénnica, especialmente a través del importante canal Preferably, the present composition contains a surfactant system conjugated by a combination of Sodium Laurileter Sulfate and Polysorbate-20, which increases and improves the contact of the active ingredients on the scalp, increasing its levels of intradenic penetration, especially through the important channel
folicular, generalmente bloqueado a causa de las secreciones grasas del bulbo sebáceo. follicular, usually blocked due to fatty secretions of the sebaceous bulb.
Con ello se consigue una mejora de la biodisponibilidad y eficacia del producto en la This results in an improvement in the bioavailability and efficacy of the product in the
zona basal del folículo pilífero. basal area of the hair follicle.
De forma preferida la presente invención se refiere a una composición cosmética para la preparación de una composición cosmética para el cuidado y tratamiento de la alopecia que comprende los siguientes componentes en las siguientes proporciones, de manera Preferably, the present invention relates to a cosmetic composition for the preparation of a cosmetic composition for the care and treatment of alopecia comprising the following components in the following proportions, so
que la suma de los mismos no supere el 100% de la composición: that the sum of them does not exceed 100% of the composition:
- Fracción activa de extracto orgánico de Active fraction of organic extract of
- brotes de gui sante buds of gui sante
- (Pisum sativum): entre O, 10% Y 5,00 % (Pisum sativum): between 0, 10% and 5.00%
- Pantotenato Cálcico: Calcium Pantothenate:
- entre 0, 10% y 1,50 % between 0, 10% and 1.50%
- Arginina: Arginine:
- entre 0,10% y 1,50 % between 0.10% and 1.50%
- Cafeína: Caffeine:
- 0,50% 0.50%
- Acido Pirrolidoncarboxílico, sa l de Zinc : Pyrrolidoncarboxylic acid, zinc salt:
- entre 0,50% y 4,00% between 0.50% and 4.00%
- Laurileter Sulfato Sódico al 27%: 27% Sodium Lauryl Sulfate:
- entre I ,00% Y 5,00% between I, 00% and 5.00%
- Polisorbato-20: Polysorbate-20:
- entre 1,00% Y 5,00% between 1.00% and 5.00%
- Conservante: Preservative:
- entre O, I 0% Y 0,50% between O, I 0% and 0.50%
- Acido Cítrico a pH 5,5: Citric Acid at pH 5.5:
- entre 0,0 I 0% Y 0,50% between 0.0 I 0% and 0.50%
- Agua: Water:
- q.s. q.s.
De fanTIa preferida el conservante es una mezcla de Fenoxietanol con Diazolidinil Urea, Benzoato Sódico, Metilparaben y Propilparaben. The preferred preservative is the mixture of Phenoxyethanol with Diazolidinyl Urea, Sodium Benzoate, Methylparaben and Propylparaben.
Aspectos adicionales de la presente invención protegen la aplicación de la composición Additional aspects of the present invention protect the application of the composition
de la presente invención de fonna tópica en forma de crema, espuma, loción O emulsión. Preferentemente de aplicación tópica mediante un dispositivo de tubo con aplicador para su dispensación en forma de espuma sin necesidad de propelente en aerosol. of the present invention of topical fonna in the form of cream, foam, lotion or emulsion. Preferably for topical application by means of a tube device with an applicator for dispensing in the form of foam without the need for aerosol propellant.
Según otro aspecto la presente invención protege el uso de la composición cosmética anteriormente citada para la preparación de una composición cosmética para el cuidado y tratamiento de la alopecia, generalmente por vía tópica en forma de crema, espuma, loción O emulsión. así como el uso de dicha composición para estimular el crecimjento, nutrir el bulbo pilífero, fortificar la raíz del cabello y estimular el riego sanguíneo del cuero cabelludo. According to another aspect, the present invention protects the use of the aforementioned cosmetic composition for the preparation of a cosmetic composition for the care and treatment of alopecia, generally topically in the form of cream, foam, lotion or emulsion. as well as the use of said composition to stimulate growth, nourish the hair bulb, fortify the hair root and stimulate blood flow to the scalp.
La presente invención protege asimismo el método de aplicación sobre el cuero cabelludo de dicha composición que comprende las etapas de tomar una muestra de la composición cosmética con un dispositivo de aplicación y aplicar de fonna local izada sobre el área afectada. The present invention also protects the method of application on the scalp of said composition, which comprises the steps of taking a sample of the cosmetic composition with an application device and applying locally raised hair on the affected area.
Las propiedades beneficiosas de esta crema se deben a la selección y proporción de cada uno de los componentes de la composición. The beneficial properties of this cream are due to the selection and proportion of each of the components of the composition.
Por ejemplo el extracto orgánico de guisante, es un extracto vegetal a base de brotes de guisantes orgánicos, que reactiva el crecimiento del cabello actuando directamente sobre las células de la papila dérmica las cuales son clave para el ciclo de crecimiento del cabello. Gracias a su doble acción, el extracto orgánico de guisante amplifica eficazmente la expresión del gen noggin, que resulta en un período de reposo más corto, y aumenta la expresión del FGF-7 (factor de crecimiento de fibroblastos -7). Esto a su vez estimula la proliferación de las células pilosas para desencadenar la fase de crecimiento anágena. For example, the organic pea extract is a plant extract based on organic pea sprouts, which reactivates hair growth by acting directly on the cells of the dermal papilla which are key to the hair growth cycle. Thanks to its double action, the organic pea extract effectively amplifies the expression of the noggin gene, which results in a shorter rest period, and increases the expression of FGF-7 (fibroblast growth factor -7). This in turn stimulates the proliferation of hair cells to trigger the anagen growth phase.
La sal de zinc del ácido pirrolidoncarboxílico (zinc peA), o Zinc L-ácido pirrolidona carboxílico tiene varias funciones importantes en la piel y en el cuero cabelludo. Se presenta tanto en fonna de sal como de ácido zinc peA. Su función fundamental consiste en inhibir la catalasa para limitar la producción de DHT (Dihidroxitestosterona). La DHT es responsable de la producción de sebo de las glándulas sebáceas, asi como la constricción del flujo sanguineo en el cuero cabelludo. Otros beneficios incluyen las propiedades frente a bacterias y hongos, controlando secundariamente el olor que surge de sobrecrecimiento bacteriano. The zinc salt of pyrrolidoncarboxylic acid (zinc peA), or Zinc L-pyrrolidone carboxylic acid has several important functions in the skin and scalp. It occurs in both salt and zinc peA acid. Its fundamental function is to inhibit catalase to limit the production of DHT (Dihydroxystestosterone). DHT is responsible for sebum production of the sebaceous glands, as well as the constriction of blood flow in the scalp. Other benefits include the properties against bacteria and fungi, secondarily controlling the smell that arises from bacterial overgrowth.
La arginina, (arg o R) es uno de los 20 aminoácidos que se encuentran fonnando parte de las proteínas. En el tejido hepático, la arginina puede ser sintetizada en el ciclo de la omitina (o ciclo de la urea). Se clasifica, en población pediátrica, como un aminoácido esencial. Este aminoácido se encuentra involucrado en muchas de las actividades de las glándulas endocrinas. Una de sus funciones tiene que ver con la circulación en sangre (potencia los efectos vasodilatadores), por lo que puede resultar beneficiosa para problemas coronarios, para los dolores en las piernas, el riñón y para el cabello. Arginine, (arg or R) is one of the 20 amino acids found in part of the proteins. In liver tissue, arginine can be synthesized in the omitin cycle (or urea cycle). It is classified, in pediatric population, as an essential amino acid. This amino acid is involved in many of the activities of the endocrine glands. One of its functions has to do with blood circulation (potentiates the vasodilator effects), so it can be beneficial for coronary problems, for pain in the legs, kidney and hair.
La cafeína es un alcaloide sólido de la serie púrica; es una sustancia que existe de fonna natural en algunas plantas, siendo el café y el té las más conocidas, aunque también se puede producir de manera artificial. En las plantas actúa como un pesticida natural, matando los insectos que se alimentan de ellas. Cuando la ingerimos actúa como un estimulante del sistema nervioso, produciendo un incremento en la energía. Se elimina de fonna natural a través de la orina. Caffeine is a solid alkaloid of the Puric series; It is a substance that exists from natural sources in some plants, with coffee and tea being the best known, although it can also be produced artificially. In plants it acts as a natural pesticide, killing insects that feed on them. When we eat it acts as a stimulant of the nervous system, producing an increase in energy. It is eliminated from natural sources through urine.
Una de las características de la cafeína es que provoca vasoconstricción, con lo que reduce el enrojecimiento de la piel en personas con rosácea. También es ideal en cosméticos específicos para reducir las bolsas de los ojos por su acción antiinflamatoria, en productos protectores a la exposición a los rayos UV-B, gracias a su poder antioxidante, o en productos anticelulitis, ya que aumenta la microcirculación. Por último, la cafeína reduce la agregación plaquetaria y aumenta el flujo sanguineo y el suministro de nutrientes a las raices del pelo del cuero cabelludo. One of the characteristics of caffeine is that it causes vasoconstriction, thereby reducing the redness of the skin in people with rosacea. It is also ideal in specific cosmetics to reduce eye bags due to its anti-inflammatory action, in protective products against exposure to UV-B rays, thanks to its antioxidant power, or in anti-cellulite products, since it increases microcirculation. Finally, caffeine reduces platelet aggregation and increases blood flow and nutrient supply to the roots of scalp hair.
La vitamina 85 (o ácido pantoténico) es de gran importancia tanto para el crecimiento de las uñas, la regeneración de la piel, así como también para la salud del cabello. Cuando se habla de esta vitamina en referencia a los problemas capilares, no se está diciendo que funcione como solución para ese tipo de disfunciones sino que su acción es de especial imponancia para el cabello como nutriente, y en ningún caso debe faltar. De manera que, no hay que confundir aquello que favorece la salud capilar y simplemente funciona como un aporte saludable, con aquello que utilizamos como solución directa a la caída del cabello, que generalmente se refiere a los fánnacos. Vitamin 85 (or pantothenic acid) is of great importance for both nail growth, skin regeneration, as well as hair health. When talking about this vitamin in reference to hair problems, it is not being said to work as a solution for this type of dysfunction but its action is especially important for the hair as a nutrient, and in no case should it be missing. So, do not confuse what favors hair health and simply works as a healthy contribution, with what we use as a direct solution to hair loss, which usually refers to the fánnacos.
De fOnTIa preferida, la presente composición contiene un sistema tensioactivo fonnado por una combinación de Laurileter Sulfato Sódico y Polisorbato-20, que aumenta y mejora el contacto de los principios activos sobre el cuero cabelludo, incrementando sus niveles de penetración intradénnica, especialmente a través del importante canal folicular, generalmente bloqueado a causa de las secreciones grasas del bulbo sebáceo. Con ello se consigue una mejora de la biodisponibilidad y eficacia del producto en la zona basal del folículo pilífero. Of preferred preference, the present composition contains a surfactant system conjugated by a combination of Sodium Laurileter Sulfate and Polysorbate-20, which increases and improves the contact of the active ingredients on the scalp, increasing its levels of intradenic penetration, especially through the important follicular canal, usually blocked because of the fatty secretions of the sebaceous bulb. This improves the bioavailability and efficacy of the product in the basal area of the hair follicle.
EJEMPLOS DE REALIZACIÓN EXAMPLES OF REALIZATION
El siguiente ejemplo específico que se proporcionan aquí sirve para ilustrar la naturaleza de la presente invención. Este ejemplo se incluye solamente con fines ilustrativos y no ha de ser interpretado como limitativo a la invención que aquí se reivindica. The following specific example provided here serves to illustrate the nature of the present invention. This example is included for illustrative purposes only and should not be construed as limiting the invention claimed herein.
Ejemplo: Fórmula ((ue produce aumento significalivo de nacimienlO de cabello. Example: Formula ((which produces a significant increase in the birth of hair.
Para el presente ejemplo se aplica en una zona del cuero cabelludo mediante masaje de fonna continuada durante 7 días justo antes de acostarse para que la composición actúe al menos durante 6 horas seguidas la composición cosmética que comprende los sib'Uientes componentes en las siguientes proporciones, de manera que la suma de los mismos no supere el 100% de la composición: For the present example, a scalp massage is applied in a zone of the scalp for 7 days just before bedtime so that the composition acts for at least 6 hours in a row, the cosmetic composition comprising the following components in the following proportions, so that the sum of them does not exceed 100% of the composition:
Fracción activa de extracto orgánico de brotes de guisante (Pisum sativum): Pantotenato Cálcico: Active fraction of organic pea sprout extract (Pisum sativum): Calcium Pantothenate:
Cafeina: Caffeine:
Laurileter Sulfato Sódico al 27%: Polisorbato-20: 27% Sodium Lauryl Sulfate: Polysorbate-20:
Acido Citrico a pH 5,5: Agua: Citric acid at pH 5.5: Water:
entre 0, 10% Y 5,00 % entre 0,10% Y 1,50 % entre 0,10% y 1,50 % 0,50% between 0.10% and 5.00% between 0.10% and 1.50% between 0.10% and 1.50% 0.50%
entre 0,50% y 4,00% between 0.50% and 4.00%
entre 1,00% y 5,00% between 1.00% and 5.00%
entre 1,00% Y 5,00% entre 0,1 0% Y 0,50% entre 0,010% Y 0,50% between 1.00% and 5.00% between 0.1 0% and 0.50% between 0.010% and 0.50%
q.s. q.s.
- 5 5
- En la que de fonna preferida el conservante es una mezcla de Fenoxietanol con Diazolidinil Urea, Benzoato Sódico, Metilparaben y Propilparaben. Tras 7 días de tratamiento se observa un incremento del nacimiento del cabello dicha zona afectada. en Where the preferred preservative is a mixture of Phenoxyethanol with Diazolidinyl Urea, Sodium Benzoate, Methylparaben and Propylparaben. After 7 days of treatment there is an increase in the birth of the hair in said affected area. in
- lO the
- 15 fifteen
Claims (8)
- mismos no supere el 100% de la composición: they do not exceed 100% of the composition:
- Fracción activa de extracto orgánico de Active fraction of organic extract of
- brotes de guisante pea sprouts
- (Pisum sativum): entre 0,10% Y 5,00 % (Pisum sativum): between 0.10% and 5.00%
- Pantotenato Cálcico: Calcium Pantothenate:
- entre 0,10% y 1,50 % between 0.10% and 1.50%
- Arginina: Arginine:
- entre 0,10% y 1,50 % between 0.10% and 1.50%
- Cafeína: Caffeine:
- 0,50% 0.50%
- Acido Pirrolidoncarboxílico, sa l de Zinc: Pyrrolidoncarboxylic acid, zinc salt:
- entre 0,50% y 4,00% between 0.50% and 4.00%
- Conservante: Preservative:
- entre 0,10% y 0,50% between 0.10% and 0.50%
- Acído Cítrico a pH 5,5: Citric Acid at pH 5.5:
- entre 0,010% y 0,50% between 0.010% and 0.50%
- Agua: Water:
- q.s. q.s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331311A ES2436246B2 (en) | 2013-09-06 | 2013-09-06 | Cosmetic composition for the care and treatment of alopecia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331311A ES2436246B2 (en) | 2013-09-06 | 2013-09-06 | Cosmetic composition for the care and treatment of alopecia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2436246A1 ES2436246A1 (en) | 2013-12-27 |
| ES2436246B2 true ES2436246B2 (en) | 2014-04-28 |
Family
ID=49753706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201331311A Active ES2436246B2 (en) | 2013-09-06 | 2013-09-06 | Cosmetic composition for the care and treatment of alopecia |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2436246B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3900792B1 (en) * | 2020-04-20 | 2022-07-13 | Dr. Kurt Wolff GmbH & Co. KG | Treatment regimen with minoxidil and caffeine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758984B1 (en) * | 1997-02-03 | 1999-04-16 | Serobiologiques Lab Sa | ACTIVE SYNERGISTIC COMPLEX AND COSMETIC AND / OR PHARMACEUTICAL PRODUCT COMPRISING THIS COMPLEX |
| AU2003257143A1 (en) * | 2002-07-31 | 2004-02-16 | Shaklee Corporation | A method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
| CN1274243C (en) * | 2004-06-22 | 2006-09-13 | 南阳市海达生物技术有限公司 | Hair tonic amino acid and its preparation method |
| CN101683344A (en) * | 2008-09-25 | 2010-03-31 | 宋宏黎 | Nutritious mixture of amino acid and vitamin for preventing hair losing and improving hair growing |
| FR2962038B1 (en) * | 2010-07-01 | 2013-01-18 | Isp Investments Inc | USE OF PEPTIDE PEA EXTRACT AS ANTIOXIDANT ACTIVE AGENT IN A COSMETIC COMPOSITION |
| GB201017634D0 (en) * | 2010-10-19 | 2010-12-01 | Pangaea Lab Ltd | Nutritional supplement |
-
2013
- 2013-09-06 ES ES201331311A patent/ES2436246B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2436246A1 (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI565467B (en) | Composition and method for stimulating hair growth | |
| CN102159179B (en) | Composition for prevention and treatment of alopecia or for hair growth | |
| US20170281506A1 (en) | Composition for topical application for preventing hair loss and stimulating hair growth | |
| JPS6345212A (en) | Improved permeable local medicinal composition | |
| US10016351B2 (en) | Composition for promoting hair growth or preventing hair loss | |
| KR102006950B1 (en) | Cosmetics compositions for hair growth promoter | |
| ES2657376T3 (en) | Composition containing the association of madecasoside and / or terminoloside and an arginine and / or one of its salts and / or one of its derivatives; use of the association to induce and / or stimulate the growth of these human keratin fibers and / or slow their fall | |
| ES2311727T3 (en) | PROCEDURE FOR STIMULATION OF HAIR GROWTH USING BENZOPIRANOS. | |
| ES2436246B2 (en) | Cosmetic composition for the care and treatment of alopecia | |
| US20230023847A1 (en) | Composition for preventing hair loss and promoting hair regrowth | |
| ES2898222T3 (en) | Composition to prevent hair loss and promote hair growth | |
| JP2022024400A (en) | Hair restorer/grower | |
| US20160354293A1 (en) | Composition for promoting hair growth or preventing hair loss | |
| ES2347512B1 (en) | FOLICULO-STIMULATING COSMETIC LOTION TO REGENATE KERATIN AND MANUFACTURING PROCEDURE. | |
| TWI715838B (en) | Uses of a composition in the manufacture of medicaments for promoting hair growth, preventing hair loss or promoting the proliferation of hair follicle stem cells in a subject | |
| KR20170038321A (en) | Composition for improving a scalp condition and/or promoting hair growth and/or restoration containing tectorigenin | |
| US9849078B2 (en) | Plant extract for hair tonic for treating baldness and preventing hair loss and hair bulb regenerator | |
| JPH08291026A (en) | Hair generating and growing agent | |
| KR102465464B1 (en) | Composition for Hair care comprising Vitagen | |
| CA2874288A1 (en) | Composition for hair growth | |
| ES2212753B2 (en) | FORMULA THAT BRAKES THE ALOPECIA AND PROVIDES THE BIRTH OF THE HAIR. | |
| JP2003267864A (en) | Hair-restoring and growing agent | |
| ES2315115B1 (en) | NEW CAPILLARY SOLUTION CONCENTRATED BASED ON MINOXIDIL. | |
| ES2784026T3 (en) | Non-therapeutic use of a composition to promote hair growth | |
| ES2613888B1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALOPECIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC2A | Transfer of patent |
Owner name: CNCE INNOVACION, S.L. Effective date: 20140213 |
|
| FG2A | Definitive protection |
Ref document number: 2436246 Country of ref document: ES Kind code of ref document: B2 Effective date: 20140428 |